<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Compliance</title>
	<atom:link href="http://www.tapanray.in/tag/compliance/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus On Patient Compliance To Boost Pharma Sales…And More…</title>
		<link>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-patient-compliance-to-boost-pharma-salesand-more</link>
		<comments>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/#comments</comments>
		<pubDate>Mon, 20 May 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[drug companies]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[new products]]></category>
		<category><![CDATA[non-adherence]]></category>
		<category><![CDATA[noncompliance]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-compliance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9534</guid>
		<description><![CDATA[One high-impact area in the healthcare space that often finds its place in the backseat is &#8211; patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course &#8230; <a href="http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trees Die From The Top: Apt For Pharma Leadership Too?</title>
		<link>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=trees-die-from-the-top-apt-for-pharma-leadership-too</link>
		<comments>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/#comments</comments>
		<pubDate>Mon, 22 Oct 2018 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[appraisal]]></category>
		<category><![CDATA[apt]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[dies]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[metric]]></category>
		<category><![CDATA[Narasimhan]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[Tree]]></category>
		<category><![CDATA[Vas]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9229</guid>
		<description><![CDATA[The Management Guru of all-time &#8211; Peter F. Drucker once said: &#8220;The spirit of an organization is created from the top… If an organization is great in spirit, it is because the spirit of its top people is great.” As &#8230; <a href="http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rebuilding Pharma Image: A Laudable Mindset &#8211; Lacking In Many</title>
		<link>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rebuilding-pharma-image-a-laudable-mindset-lacking-in-many</link>
		<comments>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/#comments</comments>
		<pubDate>Mon, 24 Jul 2017 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[Astellas]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[codes]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[lacking]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[PMCPA]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[profession]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rebuilding]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Uniform]]></category>
		<category><![CDATA[violations]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8326</guid>
		<description><![CDATA[The fierce debate on ethics and compliance related issues in the pharma marketing practices still reverberates, across the globe. One of its key fallout has been ever-increasing negative consumer perception about this sector, sparing a very few companies, if at &#8230; <a href="http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Business Ethics, Values and Compliance: Walking the Talk</title>
		<link>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=business-ethics-values-and-compliance-walking-the-talk</link>
		<comments>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/#comments</comments>
		<pubDate>Mon, 26 Dec 2011 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[Walking]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=156</guid>
		<description><![CDATA[Wish you and your family all happiness, prosperity, peace and good health in the brand new year 2012 Business Ethics, Values and Compliance: Walking the Talk Ethical business conduct and value standards, especially of medium, large to very large corporations &#8230; <a href="http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does India need an equivalent of ‘The Physician Payment Sunshine Act’ of the US for transparency in pharmaceutical marketing?</title>
		<link>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing</link>
		<comments>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/#comments</comments>
		<pubDate>Mon, 14 Nov 2011 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[equivalent]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=175</guid>
		<description><![CDATA[Currently a strong and palpable public sentiment against corruption has engulfed India albeit more than what we witness in movements like &#8216;Occupy Wall Street&#8217; against systemic corruption not only in the US but in a large number of cities across &#8230; <a href="http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
